Information Provided By:
Fly News Breaks for January 13, 2020
GMAB
Jan 13, 2020 | 07:51 EDT
SunTrust analyst Asthika Goonewardene initiated coverage of Genmab with a Buy rating and $28 price target. The analyst sees "substantial" potential for the company's two antibody drug conjugates in cancer treatment, with topline contributions in indications with evidence of tumor response at over DKK10B. Goonewardene further cites her expectations of Genmab retaining all rights until a partnership for its bispecific antibody GEN3013 in hematology is announced.
News For GMAB From the Last 2 Days
There are no results for your query GMAB